On ECHEMI
Home > Drugs > Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
  • Founded in:

    2001-11-30
  • Country:

    China China
  • Address:

    Luoqi Road, Linyi High-tech Industrial Development Zone, Shandong Province
  • Tax NO.:

    913700002658705037
  • Registered Funds:

    60.96 million yuan
  • Website:

  • Email:

Related Drugs
Carbazochrome Sodium Sulfonate for Injection
The main component of this product is carbazochrome sodium sulfonate. Its chemical name is 1-methyl-6-oxo-2,3,5,6-tetrahydroindole-5-semicarbazone-2-sulfonic acid sodium salt trihydrate. Molecular formula: C10H11N4NaO5S3H2O, molecular weight: 376.32
Name Description Content CAS NO. Registered Holders
Carbazochrome sodium sulfonate

This product can reduce capillary permeability, enhance the retraction effect of broken capillary ends, and increase the resistance of capillaries to damage. It is often used for various types of bleeding caused by increased capillary permeability.

More

This product can reduce capillary permeability, enhance the retraction effect of broken capillary ends, and increase the resistance of capillaries to damage. It is often used for various types of bleeding caused by increased capillary permeability.

51460-26-5 33
Oxaliplatin for injection
The main ingredient of this product is oxaliplatin. Its chemical name is: (1R-trans)-(1,2-cyclohexanediamine-N,N)[oxalate (Z-)-O,O]platinum.
Name Description Content CAS NO. Registered Holders
Oxaliplatin

This product has the general toxicity of platinum compounds, species-specific cardiac toxicity, and no cisplatin-like renal toxicity or carboplatin-like bone marrow toxicity. This product acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. This product binds to DNA rapidly, taking up to 15 minutes, and can inhibit DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis, and is effective against certain cell lines resistant to cisplatin.

More

This product has the general toxicity of platinum compounds, species-specific cardiac toxicity, and no cisplatin-like renal toxicity or carboplatin-like bone marrow toxicity. This product acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. This product binds to DNA rapidly, taking up to 15 minutes, and can inhibit DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis, and is effective against certain cell lines resistant to cisplatin.

61825-94-3 56
Oxaliplatin for injection
The main ingredient of this product is oxaliplatin. Its chemical name is: (1R-trans)-(1,2-cyclohexanediamine-N,N)[oxalate (Z-)-O,O]platinum.
Name Description Content CAS NO. Registered Holders
Oxaliplatin

This product has the general toxicity of platinum compounds, with species-specific cardiotoxicity, but does not have the renal toxicity of cisplatin and the bone marrow toxicity of carboplatin. This product acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. It binds to DNA quickly, taking up to 15 minutes, and can inhibit DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis, and is effective against certain cell lines resistant to cisplatin.

More

This product has the general toxicity of platinum compounds, with species-specific cardiotoxicity, but does not have the renal toxicity of cisplatin and the bone marrow toxicity of carboplatin. This product acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. It binds to DNA quickly, taking up to 15 minutes, and can inhibit DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis, and is effective against certain cell lines resistant to cisplatin.

61825-94-3 56
Cefmetazole Sodium for Injection
Cefmetazole Sodium
Name Description Content CAS NO. Registered Holders
Cefmetazole sodium

None

More

None

56796-39-5 14
Cefmetazole Sodium for Injection
Cefmetazole Sodium
Name Description Content CAS NO. Registered Holders
Cefmetazole sodium

None

More

None

56796-39-5 14
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.